Cancer MoonShot 2020 Forms Melanoma, Sarcoma Working Group

NEW YORK (GenomeWeb) – NantHealth and Cancer MoonShot 2020 announced today that they have formed the Melanoma and Sarcoma Working Group to accelerate molecular-informed immunotherapy studies. 

The working group is composed of physicians, researchers, and oncology professors from across the US who will collaborate on identifying and developing effective immunotherapies for melanoma and sarcoma. They will specifically develop clinical trial protocols by evaluating standards of care, molecular-informed patient selection, and novel combination therapies.

Members of the working group include Columbia University's Gary Schwartz and the University of Pittsburgh Medical Center's John Kirkwood.

"The establishment of the Melanoma and Sarcoma Working Group reinforces Cancer MoonShot 2020's commitment to accelerate the war on cancer," NantHealth Founder and Cancer MoonShot 2020 Leader Patrick Soon-Shiong said in a statement. "Through the collaborative effort of these academic and industry thought leaders, we will be able to provide patients with melanoma and sarcoma with next-generation immunotherapy treatment."

The establishment of the new working group follows the creation of similar groups focusing on pediatric cancer, breast cancer, head and neck cancer, and radiation and immuno-oncology. The Cancer MoonShot 2020 aims to enroll up to 20,000 cancer patients representing 20 different tumor types in randomized clinical trials for immunotherapy combinations by 2020.

Filed Under

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.

Sponsored by
Thermo Fisher Scientific

In this webinar, the first in the “New Frontiers in Liquid Biopsy Research” series, Bea Bellosillo, head of pathology at the Hospital del Mar, will discuss her experience evaluating an early-access lung cancer panel that detects copy number variants and fusions.

Sponsored by

This webinar will discuss a new approach to amplicon sequencing that addresses the current inefficiencies of the method, such as small designs, primer drop outs, and low uniformity.

Sponsored by
Dovetail Genomics

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research. 

Sponsored by

Liquid biopsies are becoming increasingly important for the detection of actionable mutations in cancer due to tumor heterogeneity as well as the practical limitations of invasive tissue biopsies.